Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothée Le Gal

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2025
Body mass index, IGF1-related polymorphisms and risk of familial breast cancer in women with no BRCA1 or BRCA2 pathogenic variantBarbara Fritsch-Humblet, Yue Jiao, Séverine Eon-Marchais, et al.
Cancers|April 13, 2024
Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia-Telangiectasia Mutated Variant CarriersRayan Bensenane, Arnaud Beddok, Fabienne Lesueur, et al.
Breast Cancer Research : BCR|March 12, 2025
Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profileNicolas M Viart, Anne-Laure Renault, Séverine Eon-Marchais, et al.
NPJ Digital Medicine|June 15, 2026
Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier statusNicolas M Viart, Lucie Thibault, Tristan Lazard, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Familial Cancer|June 14, 2021
First international workshop of the ATM and cancer risk group (4-5 December 2019)Fabienne Lesueur, Douglas F Easton, Anne-Laure Renault, et al.
Breast Cancer Research : BCR|April 19, 2018
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriersAnne-Laure Renault, Noura Mebirouk, Laetitia Fuhrmann, et al.
Cancers|April 14, 2025
Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair GenesMaximiliano Ribeiro-Guerra, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.
International Journal of Cancer|December 28, 2020
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibilityChristine Lonjou, Séverine Eon-Marchais, Thérèse Truong, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2025
Body mass index, IGF1-related polymorphisms and risk of familial breast cancer in women with no BRCA1 or BRCA2 pathogenic variantBarbara Fritsch-Humblet, Yue Jiao, Séverine Eon-Marchais, et al.
Cancers|April 13, 2024
Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia-Telangiectasia Mutated Variant CarriersRayan Bensenane, Arnaud Beddok, Fabienne Lesueur, et al.
Breast Cancer Research : BCR|March 12, 2025
Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profileNicolas M Viart, Anne-Laure Renault, Séverine Eon-Marchais, et al.
NPJ Digital Medicine|June 15, 2026
Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier statusNicolas M Viart, Lucie Thibault, Tristan Lazard, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Familial Cancer|June 14, 2021
First international workshop of the ATM and cancer risk group (4-5 December 2019)Fabienne Lesueur, Douglas F Easton, Anne-Laure Renault, et al.
Breast Cancer Research : BCR|April 19, 2018
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriersAnne-Laure Renault, Noura Mebirouk, Laetitia Fuhrmann, et al.
Cancers|April 14, 2025
Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair GenesMaximiliano Ribeiro-Guerra, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.
International Journal of Cancer|December 28, 2020
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibilityChristine Lonjou, Séverine Eon-Marchais, Thérèse Truong, et al.
Pageof 2